Nanobac Pharmaceuticals Acquires Option to License Calgenex Technology to Treat Atherosclerosis and Prostatitis
Last Update: 9:15 AM ET Oct 3, 2007
TAMPA, Fla., Oct 03, 2007 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. ("Nanobac" or "the Company") announced today that it signed an agreement with Calgenex granting Nanobac an option to assess Calgenex' drug delivery technology for potential use with Nanobac's drug combinations used in treating atherosclerosis, prostatitis, and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.
"Today's option agreement is a testament towards our goal of evaluating the best therapeutic delivery technologies used with our compounds to treat diseases associated with pathologic calcification," commented Alex H. Edwards III Director, Nanobac Pharmaceuticals. "We will be evaluating the Calgenex technology in the context of our drug development efforts in order to improve on an important class of drugs, namely bisphosphonates."
There are a number of bisphosphonate drugs on the market including Fosamax, Evista, Actonel, and most recently Boniva. The administration of these drugs has been historically problematic. Advances in delivery mechanisms, such as enteric coatings and extended release formulas have helped with patient compliance, however challenges still exist. Nanobac is investigating the use of Bisphosphonates in combination with other approved compounds for the treatment diseases associated with soft tissue calcification, including atherosclerosis and prostatitis.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com.
SOURCE: Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348
Copyright Business Wire 2007 End of Story |
